Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCNA2 | P20248 | 2/20 | 0.45 |
| ▸ | CDK2 | P24941 | 2/20 | 0.45 |
| ▸ | CCNA1 | P78396 | 2/20 | 0.45 |
| ▸ | PTH1R | Q03431 | 6/20 | 0.44 |
| ▸ | VIPR2 | P41587 | 6/20 | 0.43 |
| ▸ | VIPR1 | P32241 | 4/20 | 0.43 |
| ▸ | SLC15A2 | Q16348 | 1/20 | 0.42 |
| ▸ | CCKBR | P32239 | 1/20 | 0.41 |
| ▸ | GLP1R | P43220 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29489934 | 0.87 | VIPR2 (0.51) | CCNA2CDK2CCNA1PTH1RVIPR2 | |
| SCHEMBL29390112 | 0.87 | VIPR2 (0.51) | CCNA2CDK2CCNA1PTH1RVIPR2 | |
| SCHEMBL29466783 | 0.76 | FOLH1 (0.44) | — | |
| SCHEMBL30118983 | 0.75 | FOLH1 (0.45) | — | |
| SCHEMBL29973246 | 0.75 | BACE1 (0.44) | PTH1R | |
| SCHEMBL29883039 | 0.73 | CYP3A4 (0.48) | CCNA2CDK2CCNA1SLC15A2 | |
| SCHEMBL28457067 | 0.72 | SLC15A2 (0.76) | SLC15A2 | |
| SCHEMBL20797727 | 0.72 | SLC15A2 (0.53) | SLC15A2 | |
| SCHEMBL28758378 | 0.71 | CYP3A4 (0.44) | — | |
| SCHEMBL31432513 | 0.71 | FOLH1 (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12409205-B2 | Nanomolecules for the treatment of inflammatory bowel diseases | NORTHWESTERN UNIVERSITY (US) | 2025-09-09 | — | — | US | claimed |
| US-20220048952-A1 | ANTI-INFLAMMATORY NANOFIBERS | NORTHWESTERN UNIVERSITY | 2022-02-17 | — | — | US | claimed |
| US-12409205-B2 | Nanomolecules for the treatment of inflammatory bowel diseases | NORTHWESTERN UNIVERSITY (US) | 2025-09-09 | — | — | US | disclosed |
| US-12187815-B2 | Anti-inflammatory nanofibers | NORTHWESTERN UNIVERSITY (US) | 2025-01-07 | — | — | US | disclosed |
| US-20220048952-A1 | ANTI-INFLAMMATORY NANOFIBERS | NORTHWESTERN UNIVERSITY | 2022-02-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12409205-B2 | Nanomolecules for the treatment of inflammatory bowel diseases | VIP, IAPP, NOD2 | CCNA2 4465/4885CDK2 4819/4885CCNA1 4499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.